These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

75 related articles for article (PubMed ID: 36036707)

  • 1. [A preview of COVID-19 vaccination and treatment].
    de Boer MGJ; Bonten MJM; Huckriede ALW
    Ned Tijdschr Geneeskd; 2022 May; 166():. PubMed ID: 36036707
    [TBL] [Abstract][Full Text] [Related]  

  • 2. mRNA vaccine-induced T cells respond identically to SARS-CoV-2 variants of concern but differ in longevity and homing properties depending on prior infection status.
    Neidleman J; Luo X; McGregor M; Xie G; Murray V; Greene WC; Lee SA; Roan NR
    Elife; 2021 Oct; 10():. PubMed ID: 34636722
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comprehensive characterization of the antibody responses to SARS-CoV-2 Spike protein finds additional vaccine-induced epitopes beyond those for mild infection.
    Garrett ME; Galloway JG; Wolf C; Logue JK; Franko N; Chu HY; Matsen FA; Overbaugh JM
    Elife; 2022 Jan; 11():. PubMed ID: 35072628
    [TBL] [Abstract][Full Text] [Related]  

  • 4. High-Resolution Linear Epitope Mapping of the Receptor Binding Domain of SARS-CoV-2 Spike Protein in COVID-19 mRNA Vaccine Recipients.
    Nitahara Y; Nakagama Y; Kaku N; Candray K; Michimuko Y; Tshibangu-Kabamba E; Kaneko A; Yamamoto H; Mizobata Y; Kakeya H; Yasugi M; Kido Y
    Microbiol Spectr; 2021 Dec; 9(3):e0096521. PubMed ID: 34756082
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Combination of a Sindbis-SARS-CoV-2 Spike Vaccine and αOX40 Antibody Elicits Protective Immunity Against SARS-CoV-2 Induced Disease and Potentiates Long-Term SARS-CoV-2-Specific Humoral and T-Cell Immunity.
    Scaglione A; Opp S; Hurtado A; Lin Z; Pampeno C; Noval MG; Thannickal SA; Stapleford KA; Meruelo D
    Front Immunol; 2021; 12():719077. PubMed ID: 34394127
    [TBL] [Abstract][Full Text] [Related]  

  • 6. An Intranasal OMV-Based Vaccine Induces High Mucosal and Systemic Protecting Immunity Against a SARS-CoV-2 Infection.
    van der Ley PA; Zariri A; van Riet E; Oosterhoff D; Kruiswijk CP
    Front Immunol; 2021; 12():781280. PubMed ID: 34987509
    [TBL] [Abstract][Full Text] [Related]  

  • 7. SARS-CoV2 variant-specific replicating RNA vaccines protect from disease following challenge with heterologous variants of concern.
    Hawman DW; Meade-White K; Archer J; Leventhal SS; Wilson D; Shaia C; Randall S; Khandhar AP; Krieger K; Hsiang TY; Gale M; Berglund P; Fuller DH; Feldmann H; Erasmus JH
    Elife; 2022 Feb; 11():. PubMed ID: 35191378
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Previous Infection Combined with Vaccination Produces Neutralizing Antibodies with Potency against SARS-CoV-2 Variants.
    Ibarrondo FJ; Hofmann C; Ali A; Ayoub P; Kohn DB; Yang OO
    mBio; 2021 Dec; 12(6):e0265621. PubMed ID: 34872349
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The British variant of the new coronavirus-19 (Sars-Cov-2) should not create a vaccine problem.
    Conti P; Caraffa A; Gallenga CE; Kritas SK; Frydas I; Younes A; Di Emidio P; Tetè G; Pregliasco F; Ronconi G
    J Biol Regul Homeost Agents; 2021; 35(1):1-4. PubMed ID: 33377359
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A Barcoded Flow Cytometric Assay to Explore the Antibody Responses Against SARS-CoV-2 Spike and Its Variants.
    Vesper N; Ortiz Y; Bartels-Burgahn F; Yang J; de la Rosa K; Tenbusch M; Schulz S; Finzel S; Jäck HM; Eibel H; Voll RE; Reth M
    Front Immunol; 2021; 12():730766. PubMed ID: 34630410
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Heterogeneous SARS-CoV-2-Neutralizing Activities After Infection and Vaccination.
    Graninger M; Camp JV; Aberle SW; Traugott MT; Hoepler W; Puchhammer-Stöckl E; Weseslindtner L; Zoufaly A; Aberle JH; Stiasny K
    Front Immunol; 2022; 13():888794. PubMed ID: 35711424
    [TBL] [Abstract][Full Text] [Related]  

  • 12. B and T cell response to SARS-CoV-2 vaccination in health care professionals with and without previous COVID-19.
    Zollner A; Watschinger C; Rössler A; Farcet MR; Penner A; Böhm V; Kiechl SJ; Stampfel G; Hintenberger R; Tilg H; Koch R; Antlanger M; Kreil TR; Kimpel J; Moschen AR
    EBioMedicine; 2021 Aug; 70():103539. PubMed ID: 34391087
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Antibody Avidity and Neutralizing Response against SARS-CoV-2 Omicron Variant after Infection or Vaccination.
    Dapporto F; Marchi S; Leonardi M; Piu P; Lovreglio P; Decaro N; Buonvino N; Stufano A; Lorusso E; Bombardieri E; Ruello A; Viviani S; Molesti E; Trombetta CM; Manenti A; Montomoli E
    J Immunol Res; 2022; 2022():4813199. PubMed ID: 36093434
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparative kinetics of SARS-CoV-2 anti-spike protein RBD IgGs and neutralizing antibodies in convalescent and naïve recipients of the BNT162b2 mRNA vaccine versus COVID-19 patients.
    Trougakos IP; Terpos E; Zirou C; Sklirou AD; Apostolakou F; Gumeni S; Charitaki I; Papanagnou ED; Bagratuni T; Liacos CI; Scorilas A; Korompoki E; Papassotiriou I; Kastritis E; Dimopoulos MA
    BMC Med; 2021 Aug; 19(1):208. PubMed ID: 34420521
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Deciphering the Role of Humoral and Cellular Immune Responses in Different COVID-19 Vaccines-A Comparison of Vaccine Candidate Genes in Roborovski Dwarf Hamsters.
    Trimpert J; Herwig S; Stein J; Vladimirova D; Adler JM; Abdelgawad A; Firsching TC; Thoma T; Sehouli J; Osterrieder K; Gruber AD; Sawitzki B; Sander LE; Cichon G
    Viruses; 2021 Nov; 13(11):. PubMed ID: 34835096
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A Methyltransferase-Defective Vesicular Stomatitis Virus-Based SARS-CoV-2 Vaccine Candidate Provides Complete Protection against SARS-CoV-2 Infection in Hamsters.
    Lu M; Zhang Y; Dravid P; Li A; Zeng C; Kc M; Trivedi S; Sharma H; Chaiwatpongsakorn S; Zani A; Kenney A; Cai C; Ye C; Liang X; Qiu J; Martinez-Sobrido L; Yount JS; Boyaka PN; Liu SL; Peeples ME; Kapoor A; Li J
    J Virol; 2021 Sep; 95(20):e0059221. PubMed ID: 34379509
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Haplotype distribution of SARS-CoV-2 variants in low and high vaccination rate countries during ongoing global COVID-19 pandemic in early 2021.
    Bui NN; Lin YT; Huang SH; Lin CW
    Infect Genet Evol; 2022 Jan; 97():105164. PubMed ID: 34848355
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A Combination Adjuvant for the Induction of Potent Antiviral Immune Responses for a Recombinant SARS-CoV-2 Protein Vaccine.
    Jangra S; Landers JJ; Rathnasinghe R; O'Konek JJ; Janczak KW; Cascalho M; Kennedy AA; Tai AW; Baker JR; Schotsaert M; Wong PT
    Front Immunol; 2021; 12():729189. PubMed ID: 34603303
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Recognition of Variants of Concern by Antibodies and T Cells Induced by a SARS-CoV-2 Inactivated Vaccine.
    Melo-González F; Soto JA; González LA; Fernández J; Duarte LF; Schultz BM; Gálvez NMS; Pacheco GA; Ríos M; Vázquez Y; Rivera-Pérez D; Moreno-Tapia D; Iturriaga C; Vallejos OP; Berríos-Rojas RV; Hoppe-Elsholz G; Urzúa M; Bruneau N; Fasce RA; Mora J; Grifoni A; Sette A; Weiskopf D; Zeng G; Meng W; González-Aramundiz JV; González PA; Abarca K; Ramírez E; Kalergis AM; Bueno SM
    Front Immunol; 2021; 12():747830. PubMed ID: 34858404
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Safety and Immunogenicity Analysis of a Newcastle Disease Virus (NDV-HXP-S) Expressing the Spike Protein of SARS-CoV-2 in Sprague Dawley Rats.
    Tcheou J; Raskin A; Singh G; Kawabata H; Bielak D; Sun W; González-Domínguez I; Sather DN; García-Sastre A; Palese P; Krammer F; Carreño JM
    Front Immunol; 2021; 12():791764. PubMed ID: 34868082
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.